Development of biosimilars in an era of oncologic drug shortages

Overview of attention for article published in Drug Design, Development and Therapy, June 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 1 news story.

Summary Merrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion.